Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Can the use of polypharmacy put patients at increased risk for hospitalization, falls, and all-cause mortality? Â
Read More »The Impact of Polypharmacy in Elderly Patients with Type 2 DiabetesÂ
Sotagliflozin: Implications in Patients Living With Chronic Kidney DiseaseÂ
A new phase 3 study on novel SGLT inhibitor shows favorable results in those living with severe renal impairment.
Read More »Role of Magnesium in Type 2 Diabetes and Stroke
Adequate amounts of magnesium in the diet could reduce the risk of type 2 and cerebral vascular incidents.Â
Read More »Associations between Prediabetes and Vascular Complications
Do patients with prediabetes share the same vascular complication risk seen in patients with T2D?
Read More »Dulaglutide Can Reduce Cognitive Impairment in Patients with T2D
A recent exploratory analysis of the REWIND trial evaluated a potential additive benefit to using a once-weekly GLP-1 RA.
Read More »Old vs. New: Which T2D Agents Have the Best Renal Outcomes?
How do DPP-4 inhibitors and sulfonylureas compare to SGLT2is and GLP-1 agonists regarding renal outcomes?
Read More »The VERTIS CV Study – SGLT-2 Inhibitors’ Cardiovascular and Renal Outcomes in T2D
This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.
Read More »Elevated HbA1c = CVD
The study aimed to investigate whether testing HbA1c will improve cardiovascular disease risk assessment.
Read More »Live Longer and Cardiovascular Disease-Free
How many years can semaglutide add to your life?
Read More »The Positives and Negatives for Continuous Glucose Monitoring in Young Children
CGM use in young children with type 1 diabetes has its benefits and challenges, according to their parents.
Read More »